Cargando…
Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
BACKGROUND: Monitoring hemophilia treatment with extended half‐life products is challenging for coagulation laboratories since factor assays may show substantial differences between results obtained with the one‐stage assay (OSA) and the chromogenic substrate assay (CSA). OBJECTIVES: The aim of this...
Autores principales: | Augustsson, Cecilia, Norström, Eva, Andersson, Nadine Gretenkort, Zetterberg, Eva, Astermark, Jan, Strandberg, Karin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590307/ https://www.ncbi.nlm.nih.gov/pubmed/33134777 http://dx.doi.org/10.1002/rth2.12421 |
Ejemplares similares
-
Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021) -
von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023) -
Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
por: Shrestha, Anshu, et al.
Publicado: (2020) -
Differences in wild-type– and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies
por: Foley, Jonathan H., et al.
Publicado: (2022) -
Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
por: Manderstedt, Eric, et al.
Publicado: (2020)